Torsdag 31 Oktober | 11:07:34 Europe / Stockholm
Svenska | English

Mentice

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2024-11-07 08:30 Kvartalsrapport 2024-Q3
2024-07-23 - Kvartalsrapport 2024-Q2
2024-05-24 - X-dag ordinarie utdelning MNTC 0.00 SEK
2024-05-23 - Årsstämma
2024-05-03 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-20 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning MNTC 0.00 SEK
2023-05-11 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-03 - Bokslutskommuniké 2022
2022-10-26 - Kvartalsrapport 2022-Q3
2022-07-21 - Kvartalsrapport 2022-Q2
2022-04-28 - Kvartalsrapport 2022-Q1
2022-04-28 - X-dag ordinarie utdelning MNTC 0.00 SEK
2022-04-27 - Årsstämma
2022-02-03 - Bokslutskommuniké 2021
2021-10-28 - Kvartalsrapport 2021-Q3
2021-07-22 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning MNTC 0.00 SEK
2021-05-06 - Årsstämma
2021-04-28 - Kvartalsrapport 2021-Q1
2021-02-04 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-13 - Kvartalsrapport 2020-Q2
2020-05-28 - X-dag ordinarie utdelning MNTC 0.00 SEK
2020-05-27 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-25 - Kvartalsrapport 2019-Q3
2019-08-29 - Kvartalsrapport 2019-Q2
2019-08-28 - Extra Bolagsstämma 2019

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Mentice är verksamt inom medicinteknik. Bolaget utvecklar medicinska instrument för endovaskulär simulering samt för träningstillfällen inom kirurgi. Programmen är utvecklade för att användas i utbildningssyfte bland sjukhus och institut. Störst verksamhet återfinns inom Nordamerika och Europa. Utöver huvudverksamheten erbjuds möjligheter till leasing, support, samt teknisk service. Huvudkontoret ligger i Göteborg.
Mentice publishes the company’s interim report for the period April - June 2024
2024-07-23 08:30:00

Net sales reaching over 100 msek and the EBITDA of 24.5 msek is the highest in the company’s history

SIGNIFICANT EVENTS DURING THE SECOND QUARTER 2024 (APR – JUN)

  • Larger repeat industry order to significant client of 2.2 MUSD was announced in May.
  • CEO Göran Malmberg decided to step down from his position at the end of the year. The recruitment of a successor has been initiated. The plan for Malmberg is to step into an advisor role coming into 2025.


SECOND QUARTER 2024 (APR - JUN)

  • Order intake amounted to 71 (77) MSEK, a decrease of -8%.
  • Net sales amounted to 101 (74) MSEK, an increase of 36%, whereof 34% organic, 1% acquired and 1% currency effect.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 24.5 (10.7) MSEK.
  • Net income for the period amounted to 17.2 (1.5) MSEK.
  • Earnings per share (EPS) were 0.67 (0.06) SEK.
  • Cash flow from operating activities amounted to 5.3 (5.2) MSEK.


SIX MONTHS 2024 (JAN - JUN)

  • Order intake amounted to 109 (135) MSEK, a decrease of -19%.
  • The order book by the end of the period was 114 (125) MSEK, a decrease of -9%.
  • Net sales amounted to 146 (139) MSEK, an increase of 5%, whereof 4% organic, 1% acquired and 0% currency effect.
  • Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 6.1 (17.9) MSEK.
  • Net income for the period amounted to -7.4 (0.0) MSEK.
  • Earnings per share (EPS) were -0.29 (0.0) SEK.
  • Cash flow from operating activities amounted to 7.2 (2.5) MSEK.

Webcast presentation of the interim report
Date: July 23, 2024
Time: 10:00 CEST

To join the presentation, please visit https://investor.mentice.com/

For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22

About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-23 08:30 CEST.

Attachments
Mentice Interim Report 2024 Q2 ENG

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden